Contraindicated (one)bortezomib will improve the amount or result of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors may possibly enhance mavacamten systemic exposure, leading to heart failure due to systolic dysfunction. Lab and/or professional medical tests (which include finish blood count) must be finished while https://ramseyr382nuc5.wizzardsblog.com/profile